Get advice for managing Multiple Sclerosis: Watch the video.

Drug interactions between Naldecon-EX Pediatric and Omnipaque 180

Results for the following 2 drugs:
Naldecon-EX Pediatric (guaifenesin/phenylpropanolamine)
Omnipaque 180 (iohexol)

Interactions between your selected drugs

phenylpropanolamine ↔ iohexol

Applies to:Naldecon-EX Pediatric (guaifenesin/phenylpropanolamine) and Omnipaque 180 (iohexol)

Before you undergo any imaging procedure where iohexol may be injected directly into the spine, let your doctor know if you are currently being treated with phenylpropanolamine. Injection of iohexol into the spine can sometimes cause seizures, and the risk may be increased if you are also using phenylpropanolamine. The interaction may be more likely if you are elderly, undergoing alcohol or drug withdrawal, have a history of seizures, or have a condition affecting the central nervous system such as a brain tumor or head trauma. Your doctor may want to withhold phenylpropanolamine for a certain length of time before and after the procedure, or you may be monitored more closely during the procedure. Since iohexol contains iodine, also let your doctor know if you are allergic to iodine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2014 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Questions about Atrial Fibrillation? Get answers from our expert. Watch Video

Close
Hide
(web1)